Study of SCY-635, Pegasys and Copegus in Hepatitis C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01265511
Recruitment Status : Completed
First Posted : December 23, 2010
Results First Posted : August 18, 2017
Last Update Posted : August 18, 2017
Information provided by (Responsible Party):
Scynexis, Inc.

Brief Summary:
This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be the last on-study visit. After the Week 24 visit, all subjects with undetectable HCV RNA will be given the option to continue treatment with standard of care for an additional 24 weeks (out to Week 48) under the care of their Principal Investigator.

Condition or disease Intervention/treatment Phase
Hepatitis C Infection Drug: Placebo Drug: SCY-635 Drug: Pegasys Drug: Copegus Phase 2

Detailed Description:


The primary objective of this Phase 2a study was to assess the effect of treatment with SCY-635, used in combination with peginterferon alfa-2a (PegIFN α-2a) and ribavirin (RBV), on hepatitis C viral replication (as measured by quantitative serum HCV RNA) in treatment-naive subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.

The secondary objective of the study was to evaluate the safety and pharmacokinetics (PK) of SCY-635 when given in combination with PegIFN α-2a and RBV.

Primary Endpoints:

Proportion of subjects in each cohort with an undetectable serum HCV RNA level at Week 4 of treatment

Secondary Endpoints:

Adverse events and clinical laboratory assessments, including tests of liver function Proportion of subjects achieving complete early virologic response (cEVR, defined as an undetectable serum HCV RNA level at Week 12) Proportion of subjects achieving partial early virologic response (pEVR, defined as a detectable serum HCV RNA level with ≥ 2 log10 reduction in serum HCV RNA from Baseline to Week 12) Proportion of subjects achieving an undetectable serum HCV RNA level at Week 24 Pharmacokinetic assessments of SCY-635 when given in combination with PegIFN α-2a and RBV; trough concentrations of PegIFN α-2a and RB

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
Study Start Date : November 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Drug: Placebo
Oral tablets given bid for 28 days
Other Name: Batch # BMR/10/731

Drug: Pegasys
180 ug prefilled syringe given once per week for up to 48 weeks

Drug: Copegus
tablets given bid for up to 48 weeks

Active Comparator: SCY-635 600 mg
SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Drug: SCY-635
SCY-635 tablets, 300 mg bid for 28 days

Drug: Pegasys
180 ug prefilled syringe given once per week for up to 48 weeks

Drug: Copegus
tablets given bid for up to 48 weeks

Primary Outcome Measures :
  1. Undetectable HCV RNA [ Time Frame: Week 4 ]

Secondary Outcome Measures :
  1. Undetectable HCV RNA [ Time Frame: Week 12 ]
  2. Partial Early Virologic Response [ Time Frame: Week 12 ]
    Proportion of subjects with detectable HCV RNA that achieve a > or = 2 log reduction in HCV RNA from baseline to Week 12

  3. Undetectable HCV RNA [ Time Frame: Week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL
  • Chronic HCV status
  • HCV genotype 1 infection and IL28B genotype of C/T or T/T
  • Liver biopsy results within 3 years prior to screening indicating the absence of cirrhosis

    *If no previous biopsy is available, a biopsy must be performed during the screening period to qualify for randomization

  • Body mass index (BMI) between 18 and 38 kg/m2
  • Laboratory variables within acceptable ranges:

    • ALT/AST < 3 × ULN;
    • HgB > 12g/dL for females, > 13 g/dL for males;
    • total WBC count > 3000/mm3 and ANC > 1500/mm3;
    • platelets > 100,000/mm3;
    • prothrombin time (or INR) ≤ 1.2 × ULN;
    • serum albumin ≥ 3.4 g/dL;
    • total bilirubin WNL;
    • serum creatinine WNL; if serum creatinine is > ULN, then calculated creatinine clearance must be > 100 mL/min (by Cockcroft-Gault formula) for subject to be eligible
  • Subjects of childbearing potential (i.e., not surgically sterile or postmenopausal) must agree to use 2 forms of contraception from Screening until 24 weeks after completion of treatment with RBV
  • Negative urine testing for amphetamines and cocaine at Screening.
  • If female, the subject has a negative pregnancy test at Screening and on study Day 1

Exclusion Criteria:

  • History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease
  • Females who are pregnant or breastfeeding
  • Males with partners who are pregnant or are planning to become pregnant
  • HCV genotype other than genotype 1 and an IL28B genotype of C/C
  • Seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg)
  • Use of any investigational agent within 3 months prior to dosing
  • Received any prior FDA-approved or investigational drug or drug regimen for the treatment of hepatitis C
  • Evidence of cirrhosis on a previous liver biopsy
  • Evidence of decompensated liver disease
  • Recipient of an organ transplant
  • Evidence of hepatocellular carcinoma
  • Evidence of ongoing alcohol or substance abuse
  • Poorly-controlled diabetes mellitus
  • Congestive heart failure or unstable cardiopulmonary condition, renal disease, or hemoglobinopathy (sickle cell anemia or thalassemia
  • History of seizure disorder
  • History of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or psychosis requiring medication
  • Concurrent medical condition or laboratory abnormality that would constitute a contra-indication for interferon use
  • History of unstable thyroid disease that would preclude administration of interferon-based therapy
  • Medical condition that requires use of systemic corticosteroids
  • Received warfarin or other anticoagulants during the 21 days immediately prior to Screening, or is expected to require warfarin or other anticoagulants during the study.
  • One or more additional known primary or secondary causes of liver disease, other than hepatitis C
  • Any other concurrent medical condition likely to preclude compliance with the schedule of evaluations, or likely to confound the efficacy or safety observations
  • 12-lead ECG showing the following:

    • Corrected QTc interval ≥ 450 msec (Bazett's correction);
    • QRS > 120 msec;
    • Clinically significant abnormalities;
  • Severe retinopathy or other significant ophthalmological disorder
  • Use of any herbal supplements within 28 days prior to dosing.
  • The use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of treatment through Week 6

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01265511

United States, California
Quest Clinical Research
San Francisco, California, United States, 94115
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Texas
Alamo Medical Research
San Antonio, Texas, United States, 78215
Puerto Rico
Fundacion de Investigation de Diego
San Juan, Puerto Rico, 00927
Sponsors and Collaborators
Scynexis, Inc.
Principal Investigator: Andrew J Muir, MD Duke Clinical Research Institute
Principal Investigator: Keyur Patel, MD Duke Clinical Ressearch Institute

Responsible Party: Scynexis, Inc. Identifier: NCT01265511     History of Changes
Other Study ID Numbers: SCY-635-201
First Posted: December 23, 2010    Key Record Dates
Results First Posted: August 18, 2017
Last Update Posted: August 18, 2017
Last Verified: July 2017

Keywords provided by Scynexis, Inc.:
Hepatitis C

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents